Taken together, these data suggest that both MI and DCI supplementation restore various metabolic pathways that have become dysfunctional in MASLD, including lipogenesis, fatty acid uptake and elongation, as well as hepatic insulin sensitivity, overall leading to marked improvements in MASLD pathogenesis and supporting the idea that inositol supplementation could be a feasible dietary approach in combination with pharmacotherapy for MASLD and/or type 2 diabetes. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.